Article Index - HemaSphere - Wiley Online Library

Actions

Tools

Follow journal

All HemaSphere Articles

Filters

21-40 of 166 results

Relevance

Export Citation(s)Download PDF(s)

ARTICLE
Open Access

oa

Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemia
Marion Larue, Myriam Labopin, Thomas Schroeder, Xiao-jun Huang, Igor W. Blau, Johannes Schetelig, Arnold Ganser, Rose-Marie Hamladji, Wolfgang Bethge, Nicolaus Kröger, Gerard Socié, Urpu Salmenniemi, Henrik Sengeloev, Bhagirathbhai Dholaria, Bipin N. Savani, Arnon Nagler, Fabio Ciceri, Mohamad Mohty,

First published: 22 October 2024
REVIEW ARTICLE
Open Access

oa

NUP98 oncofusions in myeloid malignancies: An update on molecular mechanisms and therapeutic opportunities
Milad Rasouli, Selina Troester, Florian Grebien, Bianca F. Goemans, C. Michel Zwaan, Olaf Heidenreich,

First published: 25 September 2024

Collections: Reviews Pediatric Hematology
ARTICLE
Open Access

oa

Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real-world cohort of patients with lower-risk MDS
Paolo Mazzeo, Christina Ganster, John Wiedenhöft, Katayoon Shirneshan, Katharina Rittscher, Elzbieta B. Brzuszkiewicz, Doris Steinemann, Maximilian Schieck, Catharina Müller-Thomas, Hannes Treiber, Friederike Braulke, Ulrich Germing, Katja Sockel, Ekaterina Balaian, Julie Schanz, Uwe Platzbecker, Katharina S. Götze, Detlef Haase,

First published: 23 September 2024

Graphical Abstract
PERSPECTIVE
Open Access

oa

Are we ready for disease modification in myeloproliferative neoplasms?
Claire N. Harrison,

First published: 15 September 2024
LETTER
Open Access

oa

Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA
Christian M. Vonk, Emma L. Boertjes, Francois G. Kavelaars, Melissa Rijken, Jolinda M. L. Konijnenburg, Roxanne E. Cromwell, Bob Löwenberg, Tim Grob, Peter J. M. Valk,

First published: 15 August 2024
LETTER
Open Access

oa

Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms
Andrea Duminuco, Joshua Au Yeung, Raj Vaghela, Sukhraj Virdee, Claire Woodley, Susan Asirvatham, Natalia Curto-Garcia, Priya Sriskandarajah, Jennifer O'Sullivan, Hugues de Lavallade, Deepti Radia, Shahram Kordasti, Giuseppe Palumbo, Claire Harrison, Patrick Harrington,

First published: 08 August 2024
LETTER
Open Access

oa

Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome
Anna M. Aalbers, Paul L. A. van Daele, Virgil A. S. H. Dalm, Peter J. M. Valk, Marc H. G. P. Raaijmakers,

First published: 30 July 2024
LETTER
Open Access

oa

Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study
Michael H. Tomasson, Shinsuke Iida, Ruben Niesvizky, Mohamad Mohty, Nizar J. Bahlis, Joaquin Martinez-Lopez, Guenther Koehne, Paula Rodriguez-Otero, H. Miles Prince, Andrea Viqueira, Eric Leip, Umberto Conte, Sharon T. Sullivan, Alexander M. Lesokhin,

First published: 24 July 2024
ARTICLE
Open Access

oa

Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes
Enrico Attardi, Lucia Tiberi, Giorgio Mattiuz, Daniela Formicola, Elia Dirupo, Marco G. Raddi, Angela Consagra, Debora Vergani, Rosangela Artuso, Valeria Santini,

First published: 15 July 2024

Graphical Abstract
LETTER
Open Access

oa

Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)
Frank G. Rücker, Andrea Corbacioglu, Julia Krzykalla, Sibylle Cocciardi, Claudia Lengerke, Ulrich Germing, Gerald Wulf, Maisun A. Samra, Lino L. Teichmann, Michael Lübbert, Michael W. M. Kühn, Martin Bentz, Jörg Westermann, Lars Bullinger, Verena I. Gaidzik, Annika Meid, Sophia Aicher, Frank Stegelmann, Daniela Weber, Anika Schrade, Felicitas Thol, Michael Heuser, Arnold Ganser, Axel Benner, Hartmut Döhner, Konstanze Döhner, for the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG),

First published: 15 July 2024
ARTICLE
Open Access

oa

Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?
Baptiste Le Calvez, Maxime Jullien, Jean H. Dalle, Cécile Renard, Charlotte Jubert, Arthur Sterin, Catherine Paillard, Anne Huynh, Sarah Guenounou, Bénédicte Bruno, Virginie Gandemer, Nimrod Buchbinder, Pauline Simon, Cécile Pochon, Anne Sirvent, Dominique Plantaz, Justyna Kanold, Marie C. Béné, Fanny Rialland, Audrey Grain, Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC),

First published: 08 July 2024

Collections: Pediatric Hematology

Graphical Abstract
ARTICLE
Open Access

oa

Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real-world setting
Adrián Alegre, Mercedes Gironella, Fernando Escalante, Juan M. Bergua, Carmen Martínez-Chamorro, Aurelio López, Esther González, Abelardo Bárez, Nieves Somolinos, Ernesto P. Persona, Alexia S. Cabrera, Alfons Soler, Belén I. Rodríguez, Joaquín M. López, Yolanda González, Verónica C. Giménez, Antonia Sampol, Carolina Muñoz, David Vilanova, Marta Durán, Carlos Fernández de Larrea, Spanish Myeloma Group (GEM_PETHEMA),

First published: 04 July 2024
ARTICLE
Open Access

oa

The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness program
Alexandre Fagnan, Zakia Aid, Marie Baille, Aneta Drakul, Elie Robert, Cécile K. Lopez, Cécile Thirant, Yann Lecluse, Julie Rivière, Cathy Ignacimouttou, Silvia Salmoiraghi, Eduardo Anguita, Audrey Naimo, Christophe Marzac, Françoise Pflumio, Sébastien Malinge, Christian Wichmann, Yun Huang, Camille Lobry, Julie Chaumeil, Eric Soler, Jean-Pierre Bourquin, Claus Nerlov, Olivier A. Bernard, Juerg Schwaller, Thomas Mercher,

First published: 19 June 2024

Graphical Abstract
LETTER
Open Access

oa

Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa
Hosuk Ryou, Korsuk Sirinukunwattana, Ruby Wood, Alan Aberdeen, Jens Rittscher, Olga K. Weinberg, Robert Hasserjian, Olga Pozdnyakova, Frank Peale, Brian Higgins, Pontus Lundberg, Kerstin Trunzer, Claire N. Harrison, Daniel Royston,

First published: 13 June 2024
REVIEW ARTICLE
Open Access

oa

Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
Fabio Efficace, Rena Buckstein, Gregory A. Abel, Johannes M. Giesinger, Pierre Fenaux, Jan Philipp Bewersdorf, Andrew M. Brunner, Rafael Bejar, Uma Borate, Amy E. DeZern, Peter Greenberg, Gail J. Roboz, Michael R. Savona, Francesco Sparano, Jacqueline Boultwood, Rami Komrokji, David A. Sallman, Zhuoer Xie, Guillermo Sanz, Hetty E. Carraway, Justin Taylor, Stephen D. Nimer, Matteo Giovanni Della Porta, Valeria Santini, Maximilian Stahl, Uwe Platzbecker, Mikkael A. Sekeres, Amer M. Zeidan,

First published: 21 May 2024

Collections: Reviews
ARTICLE
Open Access

oa

Influence of donor–recipient sex on engraftment of normal and leukemia stem cells in xenotransplantation
Syed A. Mian, Linda Ariza-McNaughton, Fernando Anjos-Afonso, Remisha Gurung, Sophie Jackson, Aytug Kizilors, John Gribben, Dominique Bonnet,

First published: 21 May 2024

Collections: Gender Equity in Healthcare Multi-Journal Special Issue

Graphical Abstract
ARTICLE
Open Access

oa

Induction of AML cell differentiation using HOXA9/DNA binding inhibitors as a potential therapeutic option for HOXA9-dependent AML
Mélanie Lambert, Samy Jambon, Mohamed A. Bouhlel, Sabine Depauw, Julie Vrevin, Samuel Blanck, Guillemette Marot, Martin Figeac, Claude Preudhomme, Bruno Quesnel, David W. Boykin, Marie-Hélène David-Cordonnier,

First published: 06 May 2024

Graphical Abstract
LETTER
Open Access

oa

Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
Adrián Mosquera-Orgueira, Eduardo Arellano-Rodrigo, Marta Garrote, Iván Martín, Manuel Pérez-Encinas, María-Teresa Gómez-Casares, Alberto Hernández-Sánchez, Francisca Ferrer-Marín, Elvira Mora, Patricia Velez, Rosa Ayala, Anna Angona, Natalia de las Heras, Elena Magro, Carlos Pérez-Míguez, Davide Crucitti, María-Isabel Mata-Vázquez, María-Laura Fox, Sonia González de Villambrosía, María-José Ramírez, Ana García, Valentín García-Gutiérrez, Amparo Cáceres, María-Antonia Durán, María-Alicia Senín, José-María Raya, José A. González, Beatriz Cuevas, Blanca Xicoy, Jyoti Nangalia, Jesús M. Hernández-Rivas, Beatriz Bellosillo, Alberto Álvarez-Larrán, Juan C. Hernández-Boluda, Spanish MPN Group (GEMFIN),

First published: 20 March 2024
LETTER
Open Access

oa

Quantifying NPM1 MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?
Sebastian Schwind, Lara Bischof, Marius Bill, Juliane Grimm, Jule Ussmann, Donata Backhaus, Dominic Brauer, Tung Pham Thanh, Maximilian Merz, Georg-Nikolaus Franke, Klaus H. Metzeler, Vladan Vucinic, Marco Herling, Uwe Platzbecker, Madlen Jentzsch,

First published: 18 March 2024
LETTER
Open Access

oa

IDALLO study: A retrospective multicenter study of the SFGM-TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1-mutated AML after allogeneic hematopoietic cell transplantation
Adrien Caillet, Marion Simonet-Boissard, Edouard Forcade, Marie Robin, Marie-Thérèse Rubio, Marie-Anne Couturier, Micha Srour, Natacha Maillard, Raynier Devillier, Anne Huynh, Jean-Henri Bourhis, Célestine Simand, Sylvain Chantepie, Cyril Boisson, Marie Kroemer, Eric Deconinck, Ana Berceanu,

First published: 10 March 2024

Tools

Follow journal

HemaSphere

Applied Filters

Filters

All HemaSphere Articles

oa

Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemia

oa

NUP98 oncofusions in myeloid malignancies: An update on molecular mechanisms and therapeutic opportunities

oa

Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real-world cohort of patients with lower-risk MDS

Graphical Abstract

oa

Are we ready for disease modification in myeloproliferative neoplasms?

oa

Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA

oa

Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms

oa

Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome

oa

Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study

oa

Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes

Graphical Abstract

oa

Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)

oa

Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?

Graphical Abstract

oa

Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real-world setting

oa

The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness program

Graphical Abstract

oa

Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa

oa

Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)

oa

Influence of donor–recipient sex on engraftment of normal and leukemia stem cells in xenotransplantation

Graphical Abstract

oa

Induction of AML cell differentiation using HOXA9/DNA binding inhibitors as a potential therapeutic option for HOXA9-dependent AML

Graphical Abstract

oa

Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

oa

Quantifying NPM1 MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?

oa

IDALLO study: A retrospective multicenter study of the SFGM-TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1-mutated AML after allogeneic hematopoietic cell transplantation

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Tools

Follow journal

HemaSphere

Applied Filters

Filters

Filter by Keyword

Subject Categories

Publication Date

ACCESS STATUS

Author

Article Category

All HemaSphere Articles

Download PDFs

oa Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemia

oa NUP98 oncofusions in myeloid malignancies: An update on molecular mechanisms and therapeutic opportunities

oa Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real-world cohort of patients with lower-risk MDS

Graphical Abstract

oa Are we ready for disease modification in myeloproliferative neoplasms?

oa Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA

oa Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms

oa Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome

oa Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study

oa Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes

Graphical Abstract

oa Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)

oa Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?

Graphical Abstract

oa Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real-world setting

oa The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness program

Graphical Abstract

oa Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa

oa Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)

oa Influence of donor–recipient sex on engraftment of normal and leukemia stem cells in xenotransplantation

Graphical Abstract

oa Induction of AML cell differentiation using HOXA9/DNA binding inhibitors as a potential therapeutic option for HOXA9-dependent AML

Graphical Abstract

oa Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

oa Quantifying NPM1 MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?

oa IDALLO study: A retrospective multicenter study of the SFGM-TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1-mutated AML after allogeneic hematopoietic cell transplantation

oa

Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemia

oa

NUP98 oncofusions in myeloid malignancies: An update on molecular mechanisms and therapeutic opportunities

oa

Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real-world cohort of patients with lower-risk MDS

oa

Are we ready for disease modification in myeloproliferative neoplasms?

oa

Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA

oa

Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms

oa

Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome

oa

Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study

oa

Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes

oa

Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)

oa

Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?

oa

Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real-world setting

oa

The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness program

oa

Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa

oa

Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)

oa

Influence of donor–recipient sex on engraftment of normal and leukemia stem cells in xenotransplantation

oa

Induction of AML cell differentiation using HOXA9/DNA binding inhibitors as a potential therapeutic option for HOXA9-dependent AML

oa

Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

oa

Quantifying NPM1 MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?

oa

IDALLO study: A retrospective multicenter study of the SFGM-TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1-mutated AML after allogeneic hematopoietic cell transplantation